Overview

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

Status:
Recruiting
Trial end date:
2022-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-42847922 in adult participants with hepatic impairment when compared to healthy participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC